Reversine: Potent Aurora Kinase Inhibitor for Cancer Cell Cycle Research

Executive Summary: Reversine (6-N-cyclohexyl-2-N-(4-morpholin-4-ylphenyl)-7H-purine-2,6-diamine) is a small molecule inhibitor targeting Aurora kinases A, B, and C, with nanomolar IC₅₀ values (APExBIO, product page). Aurora kinases are essential serine/threonine kinases that regulate mitosis and chromosome segregation (Jan et al., 2025, DOI). Reversine suppresses cancer cell proliferation, induces apoptosis, and causes dedifferentiation in vitro and in vivo (APExBIO; Jan et al., 2025). The compound is insoluble in water, but is soluble in DMSO and ethanol under specific conditions. Reversine is a research-use-only reagent, not for diagnostic or therapeutic application.

Biological Rationale

Aurora kinases A, B, and C (AURKA, AURKB, AURKC) are serine/threonine kinases integral to mitotic regulation. Their functions span centrosome maturation, spindle assembly, and chromosome segregation, ensuring proper cell division (Jan et al., 2025). Dysregulation of Aurora kinase signaling leads to mitotic errors, aneuploidy, and is frequently observed in diverse cancers. Targeting Aurora kinases disrupts these processes, providing a mechanistic approach to inhibiting cancer cell proliferation and triggering apoptosis. Reversine, as a small molecule Aurora kinase inhibitor, enables researchers to dissect the consequences of mitotic checkpoint disruption with high specificity and reproducibility. The compound’s ability to induce dedifferentiation in murine myoblasts further highlights its utility in cell fate modulation studies (APExBIO).

Mechanism of Action of Reversine

Reversine functions as a competitive ATP-binding site inhibitor for Aurora kinases A (IC₅₀ = 150 nM), B (IC₅₀ = 500 nM), and C (IC₅₀ = 400 nM) (APExBIO). Aurora kinase A is responsible for centrosome maturation and spindle assembly, while Aurora kinase B regulates chromosome condensation, spindle checkpoint, and cytokinesis. Aurora kinase C’s roles overlap with B, especially during meiosis (Jan et al., 2025). By inhibiting these enzymes, Reversine blocks progression through M phase, leading to mitotic arrest, failed cytokinesis, polyploidy, or apoptosis. In cancer cells, this results in suppression of proliferation and increased cell death. Reversine also downregulates Aurora kinase expression at the transcript and protein levels in cervical cancer cell lines (HeLa, U14, Siha, Caski, C33A), further amplifying its effects.

Evidence & Benchmarks

• Reversine inhibits Aurora kinase A with an IC₅₀ of 150 nM, Aurora kinase B at 500 nM, and Aurora kinase C at 400 nM, as measured in cell-free enzymatic assays under standard buffer conditions (APExBIO, product page).
• Reversine treatment in vitro induces dedifferentiation of murine myoblasts (C2C12) within 24–48 hours, as assessed by morphological and gene expression changes (APExBIO, product page).
• In HeLa, U14, Siha, Caski, and C33A cervical cancer cells, Reversine inhibits proliferation and downregulates Aurora kinase expression, as shown by cell viability, RT-qPCR, and Western blotting (APExBIO, product page).
• In vivo, Reversine, alone or combined with aspirin, reduces tumor weight and volume in murine cervical cancer models, with increased apoptosis as measured by TUNEL staining (APExBIO, product page).
• Large-scale screening in gastruloid systems reveals that disruption of mitotic kinases, including Aurora kinases, leads to aneuploidy and altered gene expression (Jan et al., 2025, DOI).

Applications, Limits & Misconceptions

Reversine is primarily used in cancer research as a tool for interrogating mitotic checkpoints and Aurora kinase signaling. Its ability to induce dedifferentiation makes it valuable in stem cell and developmental biology studies. In high-throughput screening platforms, such as gastruloid arrays, Reversine enables analysis of mitotic regulation, cell fate, and aneuploidy (Jan et al., 2025).

Common Pitfalls or Misconceptions

• Reversine is not water-soluble; solubilization requires DMSO (≥19.65 mg/mL) or ethanol (≥6.69 mg/mL with warming/ultrasound) (APExBIO).
• It is not intended for diagnostic or therapeutic use; research use only (APExBIO).
• Long-term storage of Reversine solutions is not recommended; prepare fresh aliquots for each experiment (APExBIO).
• Reversine’s efficacy and specificity may vary across cell types and model systems; benchmarking is advised.
• It does not selectively distinguish between Aurora A, B, and C at typical working concentrations; off-target effects are possible at higher doses.

For more on advanced mechanistic insights into mitotic checkpoint modulation, see "Reversine and the Future of Mitotic Checkpoint Modulation"—this article provides a broader vision from bench to bedside, whereas the current article focuses on atomic, verifiable facts and usage parameters.

For a deeper exploration of cell cycle fidelity and checkpoint regulation, "Reversine: Unveiling Aurora Kinase Inhibition and Mitotic..." offers complementary insights; here, we emphasize practical benchmarks and cross-model reproducibility.

To unlock advanced workflows and troubleshooting, "Reversine: Advanced Aurora Kinase Inhibitor for Cancer Research" details application protocols, while this dossier expands on compound properties and experimental constraints.

Workflow Integration & Parameters

Reversine (A3760, APExBIO) is supplied as a solid, to be stored at –20°C. For use, dissolve in DMSO (≥19.65 mg/mL) or ethanol (≥6.69 mg/mL with gentle warming and ultrasonic treatment). Avoid long-term storage of solutions; use promptly after preparation. Standard working concentrations range from 100 nM to 10 μM, depending on cell type and assay. Include vehicle controls to account for solvent effects. In vitro, apply to cell cultures for 24–72 hours depending on endpoint analysis. For in vivo models, dosing regimens should be optimized based on published benchmarks and toxicity studies (APExBIO; Jan et al., 2025). High-throughput screening platforms, such as microraft-based gastruloid arrays, can incorporate Reversine to probe mitotic regulation at scale (Jan et al., 2025).

Conclusion & Outlook

Reversine is a validated, potent inhibitor of Aurora kinases, enabling precise interrogation of mitotic checkpoints and cell fate decisions in cancer and developmental models. It is supported by robust in vitro and in vivo evidence, with reproducible protocols across multiple systems. APExBIO provides Reversine (A3760) for research applications in cell cycle, apoptosis, and cancer biology. Ongoing advances in high-throughput screening and single-cell analysis will further expand the utility of Reversine in elucidating the molecular mechanisms of mitosis and tumorigenesis.